RevBio, Inc. announced that an experiment to observe Tetranite, the company's bone regenerative adhesive biomaterial, has been successfully launched aboard the International Space Station (ISS). On Saturday, November 26, 2022, the study materials were launched to the space station on SpaceX 's 26th Commercial Resupply Services mission sponsored by the ISS National Laboratory. This in vivo study, which will be conducted over the next two months on the ISS, will examine the ability of the biomaterial to regenerate bone when used in a microgravity environment where the conditions for bone growth and the ability to regenerate new bone tissue are significantly compromised.

Brian Hess, co-inventor of the material and CEO of RevBio, said, “This one-of-a-kind experiment will show the full potential of this groundbreaking technology. The results will both validate and motivate our ongoing research efforts to commercialize products in multiple indications aimed at revolutionizing treatment options for osteoporosis patients who suffer from debilitating fractures and have a poor healing prognosis. »

Giuseppe Intini, DDS, PhD, associate professor of periodontics and preventive dentistry at the University of Pittsburgh, and faculty member at the McGowan Institute for Regenerative Medicine, designed the experiment and will oversee its execution. He is supported by staff from his laboratory, including Roberta Di Carlo, PhD, a postdoctoral associate who has worked closely with the RevBio team, as well as staff from ISSNL, RevBio and the implementation partner work of the ISS National Laboratory, Leidos Innovations Corporation.

This research is the result of an earlier in vitro experiment the company conducted on the ISS that measured the biocompatibility and proliferation of osteoblast cells in the presence of Tetranite. Osteoblast cells are responsible for the production of new bone in the body. When the company participated in the MassChallenge start-up acceleration program , it received a grant for this initial project as part of the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space, Inc. (CASIS), which operates the ISS National Laboratory . In this new in vivo experiment, the bone healing process will be examined in living rodents using a calvarial defect model. A parallel experiment will be conducted on Earth to examine the differences between healing under normal and osteoporotic conditions induced by the microgravity environment of space. By early 2023, further ISS resupply missions should have brought all experimental samples back to Earth where switched tomography, tissue histology and gene expression analyzes will be performed to assess bone regeneration. Dr Intini and RevBio are expected to publish the full results of the experiment by the end of next year.

This research will directly influence RevBio's commercialization efforts in developing a series of products to treat fractures and bone defects. Along with funding these space experiments, RevBio has received substantial grants from the National Institute on Aging ( 2R44AG060881 , 1R43AG079741 ), the National Institute of Neurological Disorders and Stroke ( 1R44NS115386 ), as well as a sub-grant from Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center , funded by the National Institute of Dental and Craniofacial Research ( U24-DE029462 ).

About RevBio, Inc.

RevBio, Inc. is a clinical-stage medical device company engaged in the development and commercialization of a patented synthetic, injectable, self-curing, osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the broader dental, cranial and orthopedic markets, as well as for applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

Contacts
Michael Tiedemann
mtiedemann@revbio.com

 

Source:businesswire.com

Report Abuse